Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Design Therapeutics Inc (DSGN)

Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates GlobeNewswire - Tue Apr 28, 3:01PM CDT

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash...

DSGN : 13.30 (-2.21%)
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates GlobeNewswire - Mon Mar 9, 3:01PM CDT

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing...

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Feb 18, 7:00AM CST

CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire - Wed Nov 26, 2025

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results GlobeNewswire - Wed Nov 5, 2025

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1)  Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs...

DSGN : 13.30 (-2.21%)
Design Therapeutics Appoints Justin Gover to Board of Directors GlobeNewswire - Wed Sep 10, 2025

CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases,...

CMPS : 9.01 (-0.55%)
DSGN : 13.30 (-2.21%)
XENE : 56.13 (+0.16%)
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference GlobeNewswire - Wed Aug 27, 2025

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today...

DSGN : 13.30 (-2.21%)
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results GlobeNewswire - Thu Aug 7, 2025

Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program RESTORE-FA...

DSGN : 13.30 (-2.21%)
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 GlobeNewswire - Wed Jun 4, 2025

DSGN : 13.30 (-2.21%)
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference GlobeNewswire - Wed May 28, 2025

DSGN : 13.30 (-2.21%)

Barchart Exclusives

McDonald’s Is Down 4% and Starbucks Is Up 25% in 2026. The Better Dividend Stock Might Surprise You. Barchart - Fri May 1, 6:00PM CDT
Starbucks is up 25% in 2026 while McDonald's slipped 4%. So why might McDonald's still be the smarter dividend buy? The numbers tell a story most investors are missing. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.